Webcast - Molecular-Targeted Therapies in Lung Cancer: Practical Application of Clinical Trials Data

This accredited continuing education activity “Webcast-Molecular-Targeted Therapies in Lung Cancer: Practical applications of clinical trials data”, is recorded from the live webinar held on 7/10/2021. 

If you participated in the live webinar titled - Molecular-Targeted Therapies in Lung Cancer: Practical applications of clinical trials data on 7/10/2021 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 7/10/2021.  However, you may enroll in this activity to review the contents. 

The recorded lectures and subsequent discussions feature leading experts in lung cancer who provide a comprehensive overview of implications of actionable molecular alterations in lung cancer. 

The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with lung cancer. This program features in-depth discussions and analysis of the latest scientific findings and practice-changing advances (including the data presented at the 2021 ASCO Annual Meeting in June, 2021) in molecular testing and targeted-therapies for lung cancer. Expert faculty will utilize didactics, case-based presentations and related panel discussions, and aim to place molecular testing into clinical context and discuss how the results may effectively contribute to patient care. 

This educational activity will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:

  • Role of different platforms, including next generation sequencing, in testing for actionable molecular alterations to identify targeted therapy options in lung cancer. 
  • Current and evolving paradigms in a biomarker driven precision oncology approach for management of lung cancer.
  • Trends, challenges, controversies, and limitations of precision oncology approaches and targeted therapies in management of lung cancer. 

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, please register for the course here

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.

Target Audience

  • Oncologists
  • Oncology Nurse Practitioners & Physician Assistants 
  • Oncology Pharmacists
  • Oncology Nurses
  • Residents/Fellow
  • Researchers

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Review the role, including advantages and disadvantages, of different testing methodologies available for detecting molecular alterations in lung cancer. 
  2. Interpret results of next generation sequencing and other biomarkers predictive of response to targeted therapies in lung cancer.
  3. Plan optimal molecular-targeted adjuvant and/or extended adjuvant strategies for patients with non-metastatic NSCLC.
  4. Integrate recent advances and available clinical data to optimally sequence molecular-targeted agents in the treatment of metastatic NSCLC. 
  5. Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in clinical investigation for patients with NSCLC .
Course summary
Available credit: 
  • 3.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 3.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.
  • 0.00 Participation
Course opens: 
07/14/2021
Course expires: 
07/14/2022
Cost:
$0.00

 

This educational activity features recorded videos from the live virtual meeting held on 7/9/21. The videos are placed in the following order. Feel free to view the content that is relevant to you. Participants should claim continuing education credits to the extent of their participation.

20 minutes - Epidemiology of molecular alterations in lung cancer - Dr. Christina Merkhofer

25 minutes - Methodologies for detection of molecular driver mutations in lung cancer, a case-based discussion - Dr. Tejas Patil

20 minutes - Session 1 Q&A

25 minutes - Molecular-guided adjuvant therapy for lung cancer - Dr. Rafael Santana-Davila 

25 minutes - Molecular-guided therapy for metastatic lung cancer: Targeting EGFR, ROS1, ALK and BRAF – Dr. Kathryn Gold 

20 minutes - Molecular-guided therapy for metastatic lung cancer: Targeting MET, NTRK and RET - Dr. Wade Thomas Iams 

40 minutes - Emerging precision oncology approaches in management of lung cancer, a case-based discussion - Dr. Narjust Duma 

30 minutes - Session 2 Q&A

 

Narjust Duma, MD

Assistant Professor of Medicine

Dana-Farber Cancer Institute/Harvard University 

Learn More

Cristina Merkhofer, MD

Assistant Professor of Medicine 

University of Washington

Medical Oncologist

Seattle Cancer Care Alliance 

Learn More

Kathryn Gold, MD

Associate Professor of Medicine

University of California, San Diego

Learn More

Tejas Patil, MD

Assistant Professor of Medicine

University of Colorado

Learn More

Wade Iams, MD

Assistant Professor of Medicine

Vanderbilt University 

Learn More

Rafael Santana-Davila, MD

Associate Professor of Medicine 

University of Washington

Medical Oncologist

Seattle Cancer Care Alliance 

Learn More

Kumar Prabhash, MD

Medical Oncologist

Tata Memorial Hospital, Mumbai, India

Learn More

  

 

DISCLOSURES 

No Members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity except for the following faculties: 

  • Dr. Kumar Prabhash: Research support/Grant - Roche, Alkem, Dr Reddys, Intas, Glenmark, Biocon 
  • Dr. Rafael Santana-Davila:
  • Dr. Kathryn Gold: Consultant – AstraZeneca, Takeda, Rakuten; Research Support/Grant – Pfizer, Pharmacyclics
  • Dr. Wade Iams: Speakers Bureau – Amgen; Consultant – Genentech, G1 Therapeutics, Mirati
  • Dr. Narjust Duma: Consultant – Pfizer, AstraZeneca, Jansen, Neogenomics/Inivata, 

All relevant financial relationships of individuals in control of the content have been identified and mitigated. 

DISCUSSION OF OFF LABEL PRODUCTS

If any part of this activity will include the discussion of unapproved or investigational products, faculty discussing those products will clearly identify the product as investigational or not approved. 

 

Important Information about Claiming CME for this activity:

If you participated in the live webinar titled - Molecular-Targeted Therapies in Lung Cancer: Practical applications of clinical trials data on 7/10/2021 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 7/10/2021. However, you can still enroll in this activity and review the contents as needed.

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this enduring activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.

ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Available Credit

  • 3.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 3.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.
  • 0.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you have started watching the recorded content.